
Agreement - October 12, 2021
CombiGene and Spark Therapeutics enter gene therapy agreement
CombiGene and Spark Therapeutics have announced the signing of an exclusive collaboration and licensing agreement for CombiGene’s CG01 project, a gene therapy which aims to treat drug resistant focal epilepsy. The agreement provides Spark Therapeutics with the exclusive world-wide license to develop, manufacture and commercialize CG01. CombiGene will continue to execute certain aspects of the […]